Last reviewed · How we verify
MEDI0618
At a glance
| Generic name | MEDI0618 |
|---|---|
| Also known as | Protease-Activated Receptor 2 Antagonist |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine (PHASE2)
- Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers (PHASE1)
- A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI0618 CI brief — competitive landscape report
- MEDI0618 updates RSS · CI watch RSS
- AstraZeneca portfolio CI